Skip to main content
editorial
. 2020 Aug;12(8):3918–3920. doi: 10.21037/jtd.2020.04.45

Table 1. The discrepancy rate between primary and metastatic lesions.

Cancer type Biomarker type Discrepancy rate, % Concordance rate, % Reference
Melanoma BRAF 13.40 86.60 (8)
Breast ER 17.80 82.20 (9)
PR 45.40 54.60
HER2 13.30 86.70
Colon KRAS 8 92 (10)
BRAF 8 92
PIK3CA 7 93
Kidney PD-1 27 73 (11)
PD-L1 22 78
Lung cancer PD-L1 70 30 (1)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1; PD-1, programmed death 1.